Compare Marqeta Inc (MQ) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marqeta Inc vs Pfizer Inc — how do they compare? Marqeta Inc trades at $15.94 (market cap $1.69B), while Pfizer Inc trades at $27.87 (market cap $158.39B). The key difference: Pfizer Inc is far larger — about 93.7× Marqeta Inc's market cap, and Pfizer Inc pays a 6.19% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals.
| MQ | PFE | |
|---|---|---|
Market Cap | $1.69B | $158.39B |
Sector | Technology | Health |
52-Week High | $23.88 | $29.02 |
52-Week Low | $15.04 | $23.60 |
Enterprise Value | $1.01B | $209.89B |
Volume | — | 29,869,932 |
Dividend Yield | — | 6.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marqeta (MQ) trades at $16.26, down 1.93% on the day, with a bearish technical signal and neutral oscillators. The company shows improving fundamentals with three consecutive quarterly EPS beats and a return to positive net income projected for 2026. Recent news highlights product expansions with Google and partnerships in stablecoin-backed cards and European markets, signaling growth initiatives.
The stock offers potential upside to the $19 consensus price target, supported by earnings momentum and strategic partnerships. Key risks include high valuation multiples, intense competition in fintech, and reliance on continued execution amid moderating growth expectations in the second half of 2026.
Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.
Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
